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Abstract Systematic analysis of the function of genes can take
place at the oligonucleotide or protein level. The latter has the
advantage of being closest to function, since it is proteins that
perform most of the reactions necessary for the cell. For most
protein based (‘proteomic’) approaches to gene function, mass
spectrometry is the method of choice. Mass spectrometry can
now identify proteins with very high sensitivity and medium to
high throughput. New instrumentation for the analysis of the
proteome has been developed including a MALDI hybrid
quadrupole time of flight instrument which combines advantages
of the mass finger printing and peptide sequencing methods for
protein identification. New approaches include the isotopic
labeling of proteins to obtain accurate quantitative data by mass
spectrometry, methods to analyze peptides derived from crude
protein mixtures and approaches to analyze large numbers of
intact proteins by mass spectrometry directly. Examples from
this laboratory illustrate biological problem solving by modern
mass spectrometric techniques. These include the analysis of the
structure and function of the nucleolus and the analysis of
signaling complexes. ß 2000 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
During the 80’s and particularly the 90’s biological mass
spectrometry has become a powerful method for the charac-
terization of biomolecules such as proteins and nucleic acids.
The main driving forces for this development have been novel
ionization techniques which could transfer the biomolecules
from the liquid phase to the gas phase which make them
amenable to measurement in the mass spectrometer. The
two dominant methods are electrospray ionization [1] and
matrix assisted laser desorption ionization [2,3] which by his-
torical coincidence were introduced to large biomolecules at
the same time. With these two methods, the 90’s have seen the
application of concepts such as peptide mapping, which could
only be used on large amounts of sample before, to more
realistic protein amounts today. The detection of posttransla-
tional modi¢cations also became much easier and more sensi-
tive with these methods. In 1993 a number of groups [4^8]
published a method to correlate the mass spectrometric infor-
mation contained in a peptide mass map with the information
in the expanding protein sequence databases. Even though
‘mass ¢ngerprinting’ needed several more years to become a
practically viable method for protein identi¢cation, in retro-
spect the publication of these papers marked the turning point
at which mass spectrometry became a large scale or ‘function-
al genomics’ technique. They showed for the ¢rst time that
mass spectrometry could in principle handle large numbers of
proteins, similarly to oligonucleotide based methods. Shortly
afterwards, two methods were introduced which allowed the
use of peptide fragmentation data for much more speci¢c
identi¢cation of proteins [9^11].
During the last decade mass spectrometric instrumentation
and procedures have been improved to a remarkable degree,
increasing sensitivity of analysis and accuracy of results by
orders of magnitude. This development seems set to continue
in the future and will fuel additional advances.
In 1994, the term ‘proteomics’ was coined to designate the
large scale characterization of the entire protein complement
of a cell line, tissue or organism [12^14]. At the time, pro-
teome analysis was mainly associated with the display of
crude protein mixtures, such as tissue homogenates, on two-
dimensional gels. Di¡erences between the displayed spots in
the normal and diseased state, for example, would be mea-
sured by image analysis of the stained protein spots and
would correlate with the disease. A crucial and previously
di⁄cult step was the identi¢cation of such spots. In 1996 a
¢rst large scale protein identi¢cation project was performed
which unambiguously demonstrated that mass spectrometry
had the sensitivity, speci¢city and throughput to perform
this task [15].
Recently, attention has shifted to ‘functional proteomics’, in
which proteins are puri¢ed with a speci¢c function in mind.
Examples of such approaches are a⁄nity puri¢cation to ob-
tain binding partners of a protein of interest, puri¢cation of
an organelle, or puri¢cation of a multi-protein complex with a
de¢ned function. This type of proteomics has become very
successful and will continue to deliver answers to biological
questions which would be very hard to obtain otherwise. Be-
low, we will describe principles involved in the mass spectro-
metric analysis of proteins, review recent advances in the in-
strumentation and novel approaches in proteomics by mass
spectrometry. Finally, we will illustrate some of the functional
proteomic approaches with examples from our laboratory.
2. Mass spectrometry in proteomics and in functional genomics
In proteomics the premier task of mass spectrometry is the
identi¢cation of very low levels of protein which have been
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separated by one- or two-dimensional gel electrophoresis. Pro-
tocols for high sensitivity preparation of gel separated pro-
teins have been published [16^18]. Proteins are ¢rst degraded
into peptides by sequence speci¢c proteases such as trypsin.
Peptides are preferred for MS analysis, since proteins cannot
easily be eluted from gels without detergents like SDS (which
are detrimental to mass spectrometry) and because large pro-
teins are usually heterogeneous and hence possess no single
molecular weight which can be related to the corresponding
entry in a sequence database. The masses of a set of peptides
can be measured by matrix assisted laser desorption ionization
(MALDI) where a co-precipitate of light absorbing matrix
(usually K-cyano-4-hydroxycinnamic acid or dihydroxy ben-
zoic acid) and the peptide solution is irradiated with a short
pulse of UV light in the vacuum. Some of the released pep-
tides are ionized by attachment of protons and are accelerated
in a strong electric ¢eld. After being turned around by an
energy correcting ion mirror they are then detected on a chan-
neltron detector. The result of this measurement is a time of
£ight distribution of the peptides in the supernatant of the
trypsin digested protein (TOF mass spectrometry). After de-
termining the peak centroids and calibrating the spectrum, for
example on trypsin auto-digestion products, a set of highly
accurate peptide masses is obtained. With state of the art
MALDI mass spectrometers, peak resolution of about
10 000 and a mass accuracy of a few parts per million is
now possible. Recording the mass spectrum can be done man-
ually in a few minutes and has also been entirely automated
using fuzzy logic feedback control [19]. Fig. 1a shows the
peptide mass map obtained fully automatically from a gel
separated protein from the malaria parasite.
The MALDI peptide mass mapping, or ‘mass ¢ngerprint-
ing’ method has the advantage of being scalable. Many sam-
ples can be deposited on a single probe holder and measured
in a single run. Together with automated and high sensitivity
preparation of the proteins for analysis, hundreds of proteins
can be handled in this format.
Unfortunately, not all proteins are amenable to identi¢ca-
tion by peptide mass mapping alone. A large percentage of
human proteins are still not represented full length in se-
quence databases, small proteins sometimes do not result in
a su⁄cient number of tryptic peptides for unambiguous iden-
ti¢cation and mixtures of proteins can only be ‘deconvoluted’
to their respective entries in the databases with special inter-
pretation [20,21]. In many of those cases, a further step ^ mass
spectrometric sequencing of the peptides ^ is required.
Electrospray mass spectrometry is a di¡erent but comple-
mentary method to identify proteins [1]. A solution containing
the peptides is pumped through a metal capillary and dis-
persed at high voltage, resulting in rapidly evaporating, pep-
tide containing droplets. After desolvation, the peptide mole-
cules remain charged by attachment of one or a few protons
and are drawn into the vacuum of a mass spectrometer. In the
mass spectrometer, the ions are separated by dynamic electric
¢elds according to their mass to charge ratios. After a mass
spectrum is obtained, the instrument can be instructed to pass
only a particular ion species into a ‘collision chamber’ where
this ion species collides with nitrogen or argon gas at low
pressure. Multiple impacts result in fragmentation of the pep-
tide species, usually along the peptide bond. The C-terminal
containing fragments are designated YQ-ions and the N-termi-
nal containing fragments are designated B-ions [22]. A series
of B- or YQ-ions spells out a partial sequence given by the
molecular weight di¡erences between the fragments (for exam-
ple, a mass di¡erence between three adjacent YQ fragment ions
at masses 500, 613, and 684 would spell out the sequence IG
in the C- to N-terminal direction, where I could be isoleucine
or leucine which have the same mass and cannot be distin-
guished).
In the last few years the triple quadrupole mass spectrom-
eter, in which the ¢rst, isolating, mass spectrometer and the
part of the mass spectrometer which separates the fragments
were both of the quadrupole type, has largely been displaced
by the quadrupole time of £ight instrument. In this instru-
ment, the fragments are detected by TOF mass spectrometry,
like they are in the MALDI method. Resolution and mass
Fig. 1. a: Peptide mass map of a Plasmodium falciparum malaria
protein obtained from an in-gel digest of a spot from a 2D gel. The
list of masses unambiguously identi¢ed gene 14-3-3 in the database
with 13 peptides matching the calculated tryptic peptide masses
within 30 ppm. Two tryptic peptides (T) were used for calibration
of the spectrum. (The proteins were analyzed using the automated
analysis at Protana A/S, Odense, Denmark.) b and c: Identi¢cation
of a human protein by nanoelectrospray mass spectrometry. b: Mass
spectrum of the tryptic peptides from an in-gel digest. Marked
peaks were fragmented and correspond to peptides from Nop5.
c: Fragment mass spectrum of the doubly charged peptide ion at
m/z 664.31. The sequence tag E-Y-I/L is derived from the mass
di¡erence of peptide fragments. The sequence, together with the
start and end mass of the fragmentation series and the peptide
mass, was combined into the search string (693.34)EYL(1098.52)
and searched in a non-redundant database. The retrieved sequence
TQLYEYLQNR was matched against the tandem mass spectrum.
The position of the assigned series of N-terminal (B-ions) and C-ter-
minal (YQ-ions) are marked.
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accuracy are likewise in the range of 10 000 and low ppm,
respectively. Such high performance usually leads to unambig-
uous and straightforward identi¢cation on the basis of one or
a few peptides which have been fragmented. Fig. 1b shows the
mass spectrum of the peptides of a human protein. The pep-
tide at mass to charge ratio of 664.31 was selected and frag-
mented, resulting in the fragment mass spectrum shown in
Fig. 1c. The mass di¡erence between the marked peaks spells
the sequence EYI which, together with the mass of the peptide
and the mass of the fragments, uniquely identi¢ed the se-
quence TQLYEYLQNR in the non-redundant database con-
taining more than 350 000 proteins. Calculated fragments for
that sequence ¢t 15 fragment peaks in the spectrum within
0.05 Da. Fragmentation of several additional peptides likewise
uniquely identi¢ed the same protein in the database.
Peptide delivery from the gel supernatant after digestion of
the protein can happen in two ways: In the ‘nanoelectrospray’
approach [23^26] the peptide mixture is micropuri¢ed in a
small capillary packed with a small volume (100 nl) of reverse
phased material. Peptides are eluted into a very ¢ne tipped
‘spraying needle’ which supports sequencing runs of more
than 30 min on 1 Wl of peptide solution. Peptides can be
selected in turn for sequencing and peptide sequence tags
can be obtained on a large number of peptides. Proteins can
be identi¢ed in ‘real time’ during the experiment and the re-
mainder of the sequencing time can be focused on minor
components of a mixture or on potentially modi¢ed peptides.
This approach has proven very robust and has helped solve a
large number of important biological problems (see for exam-
ple [27^30]). In the liquid chromatography/mass spectrometry
approach (LC/MS), peptides are separated by a reversed
phase chromatograph whose e¥uent is directly coupled to
the mass spectrometer. Peptides are sequenced ‘on-line’ as
they elute from the column [31^33]. Advantages of this ap-
proach include the potential to automate sample introduction
and the fact that the peptides elute in a small volume, increas-
ing the mass spectrometric response. LC/MS is often per-
formed with an ‘ion trap’, a small relatively simple mass spec-
trometer which can automatically sequence and obtain
tandem mass spectra at relatively high sensitivity [34]. Data-
base searching is then often performed with correlating unin-
terpreted tandem mass spectra against the calculated mass
spectra of all the peptides in the database [11,35].
Most mass spectrometric facilities can now identify proteins
at about the 1 pmol level (50 to 100 ng of protein) of protein
initially applied to the gel. Specialized laboratories have
achieved sensitivities in the low ng range (weak silver stained
levels). Mass spectrometry itself is exquisitely sensitive, requir-
ing only a million or so molecules for detection. Therefore we
believe that the impressive gain in sensitivity achieved over the
last decade (more than a thousand-fold) will continue in the
future as various bottlenecks in the identi¢cation process are
addressed.
3. Novel developments in mass spectrometry and mass
spectrometric approaches to proteomics problems
3.1. MALDI quadrupole time of £ight instrument
An interesting instrument was developed recently, which
combines advantages of the MALDI peptide mapping ap-
proach and the peptide sequencing method [36,37]. Brie£y, a
MALDI ion source is placed in front of a quadrupole TOF
instrument (MALDI QSTAR). Peptide mass maps are ob-
tained by ¢rst passing the ions through the quadrupole section
and then analyzing them by the TOF part. Individual peptide
species can then be isolated, fragmented in the collision cell
and analyzed by TOF. Fig. 2 shows a schematic of the instru-
ment. In our experience, the MALDI QSTAR can achieve
sub-picomole sensitivities on gel separated proteins, and iden-
ti¢cations are very speci¢c. Throughput is currently limited by
the number of ions generated and transmitted. Developments
now under way should increase this number at least ten-fold.
We anticipate that the MALDI quadrupole time of £ight in-
strument will play a major role in proteomics as the ‘work
horse’ for protein identi¢cation.
3.2. Genome searching
To date, only protein sequence databases (usually auto-
translated from DNA sequence data) and expressed sequence
tag databases have been searched by mass spectrometric data.
It has been shown that virtually all human proteins which can
be visualized on gels can be identi¢ed in the expressed se-
quence tag databases, which now contain more than two mil-
lion single read cDNA sequences [38]. However, ESTs usually
cover only part of a protein sequence. If it were possible to
work directly with genomic sequence databases, this would in
principle allow for the identi¢cation of every peptide on which
mass spectrometric sequence information was obtained. Di⁄-
culties in genome searching include the large size of the hu-
man genome and the fact that only a few percent are protein
coding. Additionally, the exon^intron structure of most genes
cannot be accurately predicted by bioinformatics [39,40]. Re-
cent results obtained in our group [41], however, show that a
suitably modi¢ed peptide sequence tag algorithm has enough
speci¢city to uniquely locate peptides in raw genomic data.
Furthermore, the mass spectrometric data helps in predicting
the gene structure.
Fig. 2. Schematic of the MALDI quadruple time of £ight instru-
ment. Ions are created by the MALDI process and are accelerated
into the quadrupole sections. To obtain the peptide mass spectrum
sections Q0, Q1 and Q2 are all operated in transmission mode and
the ions are separated in the time of £ight mass spectrometer. After
obtaining the mass spectrum, an individual peptide species can be
selected by section Q1. This ion species is fragmented by collision
with argon or nitrogen gas in Q2. The fragments are analyzed with
very high resolution and mass accuracy in the time of £ight section.
In a single experiment many peptide ion species can be sequenced.
FEBS 23894 18-8-00
J.S. Andersen, M. Mann/FEBS Letters 480 (2000) 25^31 27
3.3. Analyzing crude mixtures of proteins without gel
electrophoresis
Several interesting approaches have been taken recently to-
wards the analysis of the proteome without the use of gel
electrophoresis. In one such approach, the protein population
is separated by a variant of capillary electrophoresis and the
intact proteins are then eluted into a Fourier transform ion
cyclotron resonance mass spectrometer (FT ICR). The FT
ICR is capable of storing the ions and measuring them at
extremely high resolution and mass accuracy using a fre-
quency based method. Measurement of several hundreds pro-
tein components from lysates of Escherichia coli or yeast has
already been shown [42]. Using a variant of the tandem mass
spectrometric method, it may also be possible to identify the
proteins ‘on-line’ as they elute into the mass spectrometer
[43,44]. Several practical problems remain to be solved for
this type of proteomic analysis to be successful. Furthermore,
as mentioned above, larger proteins, even when they can be
measured by this method, will have a molecular weight dis-
tribution rather than a single molecular weight.
In another approach, crude protein mixtures are digested in
solution without separation. The resulting peptide mixture is
then analyzed by the LC/MS method outlined above [45,46].
As the capacity of the mass spectrometer to sequence co-elut-
ing peptides increases, more and more complex protein mix-
tures can be analyzed. It is clear, however, that in any direct
analysis of very crude protein mixtures the major proteins will
tend to mask the minor components. This ‘dynamic range
problem’ is a key di⁄culty in any kind of unbiased analysis
of crude mixtures such as tissue homogenates or cell lysates.
3.4. Quantitation by mass spectrometry
The signal intensity of the peptides in the mass spectrometer
cannot directly be used to derive the quantity of the protein.
Instead the staining intensity together with a rough estimate
of the mass spectrometric response have usually been har-
nessed to determine the protein amount. Recently, isotopic
labeling methods have been introduced into mass spectromet-
ric proteome studies [47,48]. A stable isotope label is intro-
duced into one of the two samples that are to be quantitated
relatively to each other. These samples are then mixed and the
ratio between peptide with isotopic label and without, accu-
rately determines the ratio. Labels can for example be intro-
duced through N15 media, through the blocking group em-
ployed in blocking reactive cysteines in the proteins or by
derivatization of the N-termini of peptides. These techniques
now open up for accurate quantitation in a wide range of
proteomic situations.
4. Applications of mass spectrometry in proteomics
Mass spectrometry is now almost universally used as the
identi¢cation method in ‘expression proteomics’ with two-di-
mensional gels of two di¡erent biological states. Such appli-
cations are not reviewed here but can be found, for example,
in special issues of Electrophoresis as well as many recent
reviews [49^55]. A common di⁄culty in such projects has
been that it was di⁄cult to extract biological mechanism
from the up or down regulation of the abundant cellular pro-
teins which are usually displayed in such maps. Furthermore,
this approach is now superseded in many circumstances by the
powerful oligonucleotide chip approaches [56]. Instead we will
focus on some successful examples from our laboratory of
‘functional proteomics’ in which organelle puri¢cation or af-
¢nity puri¢cation was used as a direct lead into biological
function.
4.1. Multi-protein complexes
Multi-protein complexes, or ‘molecular machines’, are as-
semblies with a particular function such as splicing, transport
or nuclear import/export. One use of proteomics technology is
to determine the make up of such complexes [57,58]. To this
end, they need to be puri¢ed speci¢cally, the identity of the
factors in the complex needs to be determined and ¢nally the
in vivo presence of the novel members of the complex needs to
be established. In collaboration with Lamond’s laboratory, we
have extensively characterized the human spliceosome in this
way. The spliceosome was assembled on a model biotinylated
and radioactively labeled pre-messenger RNA. The complex
was pulled out of the radioactive fraction after gel ¢ltration
using the biotin^streptavidin system. The spliceosome associ-
ated proteins were then separated and visualized by two-di-
mensional gel electrophoresis. More than 70 protein spots
were analyzed. In a single experiment, 19 novel splicing fac-
tors were found. Interestingly, all the novel proteins could be
identi¢ed, and many cloned in a straightforward manner, us-
ing EST libraries and physical EST clones as reagents [38]. In
vivo con¢rmation of the involvement of these factors in splic-
ing was obtained by fusing novel genes with green £uores-
cence protein (GFP) and observing co-localization with
known spliceosomal protein. Several of the novel proteins
are now further being studied in our laboratories with the
help of proteomic techniques. For example, proteins can be
epitope tagged and incubated with nuclear extract. The eluted
and gel separated proteins can again be analyzed by mass
spectrometry to reveal more detailed involvement in sub-com-
plexes of the spliceosome, in this case.
A large number of multi-protein complexes has now been
analyzed, including the nuclear pore complex in yeast [59], the
spindle pole body in yeast [60], the Arp2/3 complex [61] and
Fig. 3. Isolation of proteins associated with the phosphorylated IUB/
NFUB protein complex. 35S-radiolabeled HeLa lysate was incubated
with antibody immobilized IUB/NFUB complex in the presence of
phosphorylated IUB peptide (lane 1) or serine substituted IUB pep-
tide (lane 2). The immune complexes were then washed, eluted and
analyzed by SDS^PAGE and autoradiography. Tryptic peptides de-
rived from the marked bands from both lanes were carefully investi-
gated by nanoelectrospray tandem mass spectrometry and resulted
in the identi¢cation of the E3 ligase receptor subunit of IUB [66].
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many others. The yeast ribosome [62] and the ‘interchromatin
granule’ [63] have been studied by digesting the full comple-
ment of proteins in solution and identifying as many proteins
as possible by the LC/MS method mentioned above. Crucial
issues in the large scale analysis of multi-protein complexes by
mass spectrometry are the e⁄cient tagging and puri¢cation of
the ‘bait’ with the associated ‘prey’ proteins. Advances are
being made in this area as well, for example by using two
functionalities in the tag (calmodulin binding and Z-tag [64]
or by using two epitope tags).
Chemical cross-linking is another method that can be em-
ployed to study multi-protein complexes. For example, our
laboratory has performed limited cross-linking on the
Nup85 sub-complex of the nuclear pore [65]. In addition to
the proteins in the sub-complex additional bands appear
which contain cross-linked proteins. Pairs or triplets of such
proteins yielded nearest neighbor relationships which were
used to build a crude topological model of the complex.
4.2. Signaling pathways
Proteomic methods have also been used in our laboratory
to study more transient rather than structural complexes.
Many signaling cascades are transmitted through multi-pro-
tein complexes involving sca¡olds and these complexes can be
biochemically puri¢ed. In collaboration with Ben-Neriah we
have assembled the NFUB signaling complex on beads to
which NFUB antibody was immobilized. When the NFUB
pathway is stimulated, the IUBs which normally protect the
nuclear localization sequence in NFUB are phosphorylated
and then degraded by the ubiquitination machinery. The spe-
ci¢c receptor which recognizes the phosphorylated epitope
was not known at the time of this study. In stimulated, pro-
teasome inhibited cells, the receptor was speci¢cally visualized
when the complex was incubated with a phosphorylated ver-
sus a non-phosphorylated synthetic peptide corresponding to
the sequence of IUB which is phosphorylated upon stimulation
(see Fig. 3). One-dimensional gels revealed subtle di¡erences
in eluted proteins and the corresponding bands were se-
quenced by nanoelectrospray mass spectrometry. Six di¡erent
proteins were identi¢ed in the band and the control but two of
the peptides were absent in the control. These identi¢ed a
Drosophila protein and a human EST, leading to the cloning
of the receptor (now named E3RSIUB) [66].
In a di¡erent approach, we have precipitated tyrosine phos-
phorylated proteins in the epidermal growth factor receptor
(EGFR) pathway. Cells were stimulated by EGF and phos-
phorylated proteins were precipitated by anti-phosphotyrosine
antibodies [67]. Nine proteins speci¢c to this pathway were
identi¢ed by comparison of the immuno-precipitates between
stimulated and non-stimulated cells. Interestingly, even in
such a well studied pathway, one protein, vav-2, was found
which was not previously known to be involved and a com-
pletely novel protein was cloned. Note that in this procedure,
proteins are precipitated both from the complex that forms
directly at the intracellular domain of the receptor as well as
members of the cascade that are further downstream and do
not have physical contact to the receptor.
4.3. Organelles
Apart from multi-protein complexes, organelles can also be
puri¢ed and their composition analyzed by mass spectrome-
try. Since organelles are often less well de¢ned than smaller
multi-protein complexes, the task of veri¢cation of identi¢ca-
tions becomes even more important.
Working with the laboratory of Lamond we are purifying
and identifying the components of various nuclear structures.
Fig. 4 shows a one-dimensional gel of human nucleolar pro-
teins puri¢ed from HeLa cells. Slicing the gel into pieces and
analyzing the main protein components in every slice by
MALDI mass ¢ngerprinting and nanoelectrospray peptide se-
quencing identi¢ed more than one hundred proteins. Interest-
ingly, many of the proteins did not appear on two-dimension-
al gel of the same preparation. Some of the proteins were too
large or too hydrophobic for two-dimensional gel analysis but
others also appear to have been too basic for the range of
isoelectric focusing used in our gel system (pI 3^10). We an-
ticipate that many organelles will now be puri¢ed and ana-
lyzed by mass spectrometry. For the ¢rst time it will be pos-
Fig. 4. Characterization of proteins from human nucleoli. a: 1D gel of nucleolar proteins. MALDI MS of an aliquot of the tryptic peptide
mixture from one of the slices resulted in the identi¢cation of Nop1, hnRNP A1 and B23. b: Nanoelectrospray mass spectrum of the same
peptide mixture. The major signals represent peptides from the three proteins already identi¢ed by MALDI MS. Sequencing of unexplained
peptides resulted in the identi¢cation of two additional proteins. The sequences were retrieved from di¡erent databases in real time during the
nanoelectrospray experiment. Sequencing of additional peptides predicted from the retrieved sequences therefore can be used to validate the
identi¢cation. Nanoelectrospray of peptide mixtures has a unique advantage for such an approach as compared to LC/MS because any peptide
can be selected for sequencing at any time during the experiment.
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sible to obtain an inventory of many of the basic structures of
the cell. Even more intriguingly, after the basic catalogue of
protein components is established, it is then possible to per-
turb the system to directly measure protein changes such as
recruitment of novel factors or bridging to other complexes
and structures.
5. Conclusion
As we have shown in this review, mass spectrometry is the
central technique in a wide variety of functional genomics, or
proteomics approaches to study gene function in the post-
genomics world. Mass spectrometric instrumentation contin-
ues to become more powerful and novel instrumental concepts
are being put into use. The imminent completion of the hu-
man genome will allow all human proteins to be correlated
directly with their corresponding database entries. A wide
variety of approaches to study protein function now use
mass spectrometry. Most of these are a⁄nity based, which
simultaneously addresses the problem of functional signi¢-
cance and the dynamic range problem in proteomics. Mass
spectrometry is sure to have a place as one of the fundamental
techniques in functional genomics in the developing era of
systematic biology.
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